AstraZeneca Expects Gov’t-Paid Portion Of Rx Sales To Double Under Medicare
Executive Summary
AstraZeneca anticipates that the proportion of its products paid for by the government will more than double when the Medicare Modernization Act takes effect in January
You may also be interested in...
AstraZeneca’s Gut Instinct: CEO-Designate Is Nexium Brand Builder Brennan
AstraZeneca is elevating an executive integral to the commercial success of the company's proton pump inhibitor franchise with the appointment of U.S. head David Brennan as CEO
AstraZeneca’s Gut Instinct: CEO-Designate Is Nexium Brand Builder Brennan
AstraZeneca is elevating an executive integral to the commercial success of the company's proton pump inhibitor franchise with the appointment of U.S. head David Brennan as CEO
CMS Proposes Broad Criteria For Linking Reimbursement To Data Collection
The Centers for Medicare & Medicaid Services is proposing a broad range of circumstances under which the agency could make data collection a condition for Medicare coverage of certain products and services